Boca Raton City Online – Lifestyle
Author:
Organogenesis Holdings Inc.
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
April 28, 2026
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
April 7, 2026
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
April 7, 2026
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
April 6, 2026
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
March 7, 2026